These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 28447868

  • 1. Doxorubicin-loaded liposomes: enhancing the oral bioavailability by modulation of physicochemical characteristics.
    Daeihamed M, Haeri A, Ostad SN, Akhlaghi MF, Dadashzadeh S.
    Nanomedicine (Lond); 2017 May; 12(10):1187-1202. PubMed ID: 28447868
    [Abstract] [Full Text] [Related]

  • 2. Oral delivery of doxorubicin using novel polyelectrolyte-stabilized liposomes (layersomes).
    Jain S, Patil SR, Swarnakar NK, Agrawal AK.
    Mol Pharm; 2012 Sep 04; 9(9):2626-35. PubMed ID: 22871060
    [Abstract] [Full Text] [Related]

  • 3. The limited intestinal absorption via paracellular pathway is responsible for the low oral bioavailability of doxorubicin.
    Kim JE, Cho HJ, Kim JS, Shim CK, Chung SJ, Oak MH, Yoon IS, Kim DD.
    Xenobiotica; 2013 Jul 04; 43(7):579-91. PubMed ID: 23252722
    [Abstract] [Full Text] [Related]

  • 4. Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system.
    Ke W, Zhao Y, Huang R, Jiang C, Pei Y.
    J Pharm Sci; 2008 Jun 04; 97(6):2208-16. PubMed ID: 17879294
    [Abstract] [Full Text] [Related]

  • 5. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
    Charrois GJ, Allen TM.
    Biochim Biophys Acta; 2004 May 27; 1663(1-2):167-77. PubMed ID: 15157619
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The liposomal formulation of doxorubicin.
    Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB.
    Methods Enzymol; 2005 May 27; 391():71-97. PubMed ID: 15721375
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Bile salt integrated cerasomes: A potential nanocarrier for enhancement of the oral bioavailability of idarubicin hydrochloride.
    Emzhik M, Haeri A, Javidi J, Abdollahizad E, Qaribnejad A, Rezaee E, Torshabi M, Dadashzadeh S.
    Int J Pharm; 2024 Sep 05; 662():124518. PubMed ID: 39074645
    [Abstract] [Full Text] [Related]

  • 15. Effects of lipid composition on the properties of doxorubicin-loaded liposomes.
    Sakai-Kato K, Nanjo K, Kawanishi T, Okuda H, Goda Y.
    Ther Deliv; 2015 Jul 05; 6(7):785-94. PubMed ID: 26228772
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
    Jung SH, Jung SH, Seong H, Cho SH, Jeong KS, Shin BC.
    Int J Pharm; 2009 Dec 01; 382(1-2):254-61. PubMed ID: 19666094
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.